Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 247

1.

Quantifying Importance of Major Risk Factors for Coronary Heart Disease.

Pencina MJ, Navar AM, Wojdyla D, Sanchez RJ, Khan I, Elassal J, D'Agostino RB Sr, Peterson ED, Sniderman AD.

Circulation. 2019 Mar 26;139(13):1603-1611. doi: 10.1161/CIRCULATIONAHA.117.031855.

PMID:
30586759
2.

Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia.

Sniderman AD.

Clin Chem. 2019 Feb;65(2):225-227. doi: 10.1373/clinchem.2018.298026. Epub 2018 Dec 11. No abstract available.

PMID:
30538123
3.

ApoB in clinical care: Pro and Con.

Sniderman AD, Robinson JG.

Atherosclerosis. 2019 Mar;282:169-175. doi: 10.1016/j.atherosclerosis.2018.11.001. Epub 2018 Nov 10. Review.

PMID:
30463677
4.

A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.

Thanassoulis G, Sniderman AD, Pencina MJ.

JAMA Cardiol. 2018 Nov 1;3(11):1090-1095. doi: 10.1001/jamacardio.2018.3476.

PMID:
30422172
5.

Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated.

Sniderman AD, Thanassoulis G, Wilkins JT, Furberg CD, Pencina M.

J Am Heart Assoc. 2018 Oct 2;7(19):e010049. doi: 10.1161/JAHA.118.010049. No abstract available.

6.

The spectrum of type III hyperlipoproteinemia.

Sniderman AD, de Graaf J, Thanassoulis G, Tremblay AJ, Martin SS, Couture P.

J Clin Lipidol. 2018 Nov - Dec;12(6):1383-1389. doi: 10.1016/j.jacl.2018.09.006. Epub 2018 Sep 14.

PMID:
30318453
7.

A failure of standardization or a failure of the process of standardization.

Sniderman AD, McQueen MJ.

J Clin Lipidol. 2018 Sep - Oct;12(5):1325-1326. doi: 10.1016/j.jacl.2018.05.009. Epub 2018 May 18. No abstract available.

PMID:
30318067
8.

Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding.

Sniderman AD, Couture P, Martin SS, DeGraaf J, Lawler PR, Cromwell WC, Wilkins JT, Thanassoulis G.

J Lipid Res. 2018 Jul;59(7):1266-1275. doi: 10.1194/jlr.R082271. Epub 2018 May 16.

PMID:
29769239
9.

Response by Labos et al to Letter Regarding Article, "Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression".

Labos C, Brophy JM, Smith GD, Sniderman AD, Thanassoulis G.

Arterioscler Thromb Vasc Biol. 2018 May;38(5):e87-e88. doi: 10.1161/ATVBAHA.118.310907. No abstract available.

PMID:
29695535
10.

Evaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regression-Brief Report.

Labos C, Brophy JM, Smith GD, Sniderman AD, Thanassoulis G.

Arterioscler Thromb Vasc Biol. 2018 Jan;38(1):262-265. doi: 10.1161/ATVBAHA.117.310052. Epub 2017 Nov 9.

PMID:
29122815
11.

Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease: Insights from the National Health and Nutrition Examination Survey.

Burstein B, Altobelli KK, Williams K, Cannon CP, Pencina MJ, Sniderman AD, Thanassoulis G.

Circulation. 2017 Nov 7;136(19):1860-1862. doi: 10.1161/CIRCULATIONAHA.117.029102. No abstract available.

PMID:
29109198
12.

Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.

Verma AA, Jimenez MP, Subramanian SV, Sniderman AD, Razak F.

Circ Cardiovasc Qual Outcomes. 2017 Sep;10(9). pii: e003764. doi: 10.1161/CIRCOUTCOMES.117.003764.

PMID:
28912201
13.

Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment.

Sniderman AD, Peterson ED.

JAMA. 2017 Sep 12;318(10):915-917. doi: 10.1001/jama.2017.11750. No abstract available.

PMID:
28846117
14.

The Benefit Model for Prevention of Cardiovascular Disease: An Opportunity to Harmonize Guidelines.

Thanassoulis G, Pencina MJ, Sniderman AD.

JAMA Cardiol. 2017 Nov 1;2(11):1175-1176. doi: 10.1001/jamacardio.2017.2543. No abstract available.

PMID:
28793137
15.

Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte.

Sniderman AD, Kiss RS, Reid T, Thanassoulis G, Watts GF.

Clin Sci (Lond). 2017 May 1;131(9):791-797. doi: 10.1042/CS20160872.

PMID:
28424373
16.

Comparison of Recommended Eligibility for Primary Prevention Statin Therapy Based on the US Preventive Services Task Force Recommendations vs the ACC/AHA Guidelines.

Pagidipati NJ, Navar AM, Mulder H, Sniderman AD, Peterson ED, Pencina MJ.

JAMA. 2017 Apr 18;317(15):1563-1567. doi: 10.1001/jama.2017.3416.

17.

Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women.

Lawler PR, Akinkuolie AO, Ridker PM, Sniderman AD, Buring JE, Glynn RJ, Chasman DI, Mora S.

Clin Chem. 2017 Apr;63(4):870-879. doi: 10.1373/clinchem.2016.264515. Epub 2017 Feb 7.

18.

Variants in ANGPTL4 and the Risk of Coronary Artery Disease.

Sniderman AD, Thanassoulis G.

N Engl J Med. 2016 Dec 8;375(23):2304. doi: 10.1056/NEJMc1607380. No abstract available.

PMID:
27959692
19.

Temporal Changes in the Association Between Modifiable Risk Factors and Coronary Heart Disease Incidence.

Navar AM, Peterson ED, Wojdyla D, Sanchez RJ, Sniderman AD, D'Agostino RB Sr, Pencina MJ.

JAMA. 2016 Nov 15;316(19):2041-2043. doi: 10.1001/jama.2016.13614. No abstract available. Erratum in: JAMA. 2016 Dec 13;316(22):2433.

20.

Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis-Brief Report.

Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G.

Arterioscler Thromb Vasc Biol. 2016 Dec;36(12):2421-2423. Epub 2016 Oct 20.

PMID:
27765771

Supplemental Content

Loading ...
Support Center